| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 03/27/2013 | CN102488664B Pharmaceutical composition containing 12 vitamins |
| 03/27/2013 | CN102335266B Health care product for supplementing calcium |
| 03/27/2013 | CN102335199B Microwave-hydrolyzation method of pearl powder |
| 03/27/2013 | CN102327324B Mulberry leaf total alkali extract and preparation method and application thereof |
| 03/27/2013 | CN102308989B Health care composition of formica rufa, grape and propolis extracts |
| 03/27/2013 | CN102293941B Chinese medicinal composition for treating diabetes mellitus |
| 03/27/2013 | CN102274453B Traditional Chinese medicine for treating diabetes and preparation method thereof |
| 03/27/2013 | CN102266323B Composition of ezetimibe and simvastatin and preparation method thereof |
| 03/27/2013 | CN102247416B Blood lipid lowering application of total saponins of panax japonicus |
| 03/27/2013 | CN102234281B Pyrimidine-fused cyclic derivative |
| 03/27/2013 | CN102205066B Traditional Chinese medicine (TCM) for treating diabetes |
| 03/27/2013 | CN102188613B Traditional Chinese medicine preparation for treating diabetes |
| 03/27/2013 | CN102166259B Method for preparing biflavone capsules and tablets |
| 03/27/2013 | CN101921772B Human antibodies that bind human IL-12 and methods for producing |
| 03/27/2013 | CN101914164B Application of polysaccharide from mulberry leaves in preventing and treating diabetes |
| 03/27/2013 | CN101869303B Method for producing biological active calcium |
| 03/27/2013 | CN101836987B Compound niacin sustained release tablet |
| 03/27/2013 | CN101829199B Application of ranunculus japonicus extract in preparing anti-tumor and anti-tumor angiogenesis drugs |
| 03/27/2013 | CN101801373B Antidiabetic pharmaceutical composition |
| 03/27/2013 | CN101780215B Refining method of traditional Chinese medicine composition water extract containing ginseng |
| 03/27/2013 | CN101768081B Inhibitor of fatty acid synthase and application thereof |
| 03/27/2013 | CN101745027B Preparation method of xiaokeling condensed pill |
| 03/27/2013 | CN101678060B Medicinal herbal extract having anti-obesity effect |
| 03/27/2013 | CN101632769B Chinese medicinal composition for regulating blood sugar and preparation method thereof |
| 03/27/2013 | CN101627028B Substituted diazepan compounds as orexin receptor antagonists |
| 03/27/2013 | CN101616665B Composition useful for the treatment of type 2 diabetes |
| 03/27/2013 | CN101590239B Pharmaceutical composition containing uretic, statin and folic acid as well as applications thereof |
| 03/27/2013 | CN101479287B Crystalline solvates and complexes of (is) -1, 5-anhydro-l-c- (3- ( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes |
| 03/27/2013 | CN101381409B N-terminally chemically modified protein compositions and methods |
| 03/27/2013 | CN101243056B Crystal of phenylalanine derivative, process for producing the same and use thereof |
| 03/27/2013 | CN101137390B Novel angiogensis inhibitor |
| 03/27/2013 | CN101066997B Human antibodies that bind human IL-12 and methods for producing |
| 03/27/2013 | CN101037409B Process for the preparation of n-substituted 2-cyanopyrrolidines |
| 03/26/2013 | US8404805 Characterization of GRP94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
| 03/26/2013 | US8404726 Activating agent for peroxisome proliferator activated receptor δ |
| 03/26/2013 | US8404695 Pyrimidinyl pyridone inhibitors of JNK |
| 03/26/2013 | US8404684 Inhibitors of phosphatidylinositol 3-kinase |
| 03/26/2013 | US8404676 Oxadiazole diaryl compounds |
| 03/26/2013 | US8404639 Methods and kits for treating disease by administering insulin-like growth factor binding protein-2 |
| 03/26/2013 | US8404637 GIP analog and hybrid polypeptides with selectable properties |
| 03/26/2013 | US8404250 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation |
| 03/26/2013 | US8404226 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 03/26/2013 | CA2631737C Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes |
| 03/26/2013 | CA2545752C Treatment and prevention of liver disease associated with parenteral nutrition (pn) |
| 03/26/2013 | CA2457925C Fatty acid analogues for the treatment of inflammatory and autoimmune disorders |
| 03/21/2013 | WO2013039969A1 METHODS FOR REDUCING LIPOPROTEIN(a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) |
| 03/21/2013 | WO2013039140A1 Fused heterocyclic derivative |
| 03/21/2013 | WO2013038136A1 BI-AROMATIC AND TRI-AROMATIC COMPOUNDS AS NADPH OXIDASE 2 (Nox2) INHIBITORS |
| 03/21/2013 | WO2013037985A1 Pharmaceutical combinations including anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
| 03/21/2013 | WO2013037984A1 Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
| 03/21/2013 | WO2013037889A2 Vaccine |
| 03/21/2013 | WO2013037857A1 Cynara scolymus extracts for the treatment of dyslipidaemia |
| 03/21/2013 | WO2013037838A1 Polymorphic form of pitavastatin calcium |
| 03/21/2013 | WO2013037390A1 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| 03/21/2013 | WO2013037333A1 6, 8- disubstituted purine compositions and their pharmaceutical and cosmetic use |
| 03/21/2013 | WO2013037267A1 Variant of liraglutide and conjugate thereof |
| 03/21/2013 | WO2013037266A1 Method for solid phase synthesis of liraglutide |
| 03/21/2013 | WO2013037065A1 Microrna inhibitors |
| 03/21/2013 | WO2013014654A3 Formulas comprising highly soluble elements and vitamin for the prevention and amelioration of osteoporosis |
| 03/21/2013 | WO2012162108A9 Boron-containing compositions and methods therefor |
| 03/21/2013 | WO2012154009A3 Thienopyrimidine derivatives, pharmaceutically acceptable salts thereof, method for preparing thienopyrimidine derivatives, and pharmaceutical composition containing thienopyrimidine derivatives as active ingredients for preventing or treating diabetes-related diseases |
| 03/21/2013 | WO2012085648A9 Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof |
| 03/21/2013 | US20130072540 RNA interference of galectin-3 expression and methods of use thereof |
| 03/21/2013 | US20130072522 Process for Making Modulators of Cystic Fibrosis Transmembrane Conductance Regulator |
| 03/21/2013 | US20130072509 Pterostilbene and statin combination for treatment of metabolic disease, cardiovascular disease, and inflammation |
| 03/21/2013 | US20130072493 N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS |
| 03/21/2013 | US20130072492 Soluble guanylate cyclase activators |
| 03/21/2013 | US20130072481 mTOR SELECTIVE KINASE INHIBITORS |
| 03/21/2013 | US20130072468 Substituted piperazines as cb1 antagonists |
| 03/21/2013 | US20130072459 Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same |
| 03/21/2013 | US20130072426 Diagnostic methods for obesity and related disorders |
| 03/21/2013 | US20130072425 Saposin-a derived peptides and uses thereof |
| 03/21/2013 | US20130072421 Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
| 03/21/2013 | US20130071493 Dietary supplement containing alkaline electrolyte butters |
| 03/21/2013 | US20130071491 Extruded Legume Food Products Containing Yeast Autolysate |
| 03/21/2013 | US20130071435 Novel herbal formulation for the modulation of immune system of hiv infected patients and a process of preparation thereof |
| 03/21/2013 | US20130071408 Methods for Diagnosis and Treatment of Non-Insulin Dependent Diabetes Mellitus |
| 03/21/2013 | US20130071405 Antibodies to pcsk9 and uses thereof |
| 03/21/2013 | US20130071320 Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| 03/21/2013 | CA2855955A1 Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases |
| 03/21/2013 | CA2848487A1 Vaccine |
| 03/21/2013 | CA2848201A1 Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9) |
| 03/21/2013 | CA2847915A1 Pharmaceutical combinations including anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
| 03/21/2013 | CA2845708A1 Cynara scolymus extracts for the treatment of dyslipidaemia |
| 03/21/2013 | CA2844577A1 Microrna inhibitors |
| 03/20/2013 | EP2570414A1 Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 03/20/2013 | EP2570136A2 Protein A compositions and methods of use |
| 03/20/2013 | EP2570135A1 Vaccine |
| 03/20/2013 | EP2569429A1 Compositions and methods for modulating metabolism |
| 03/20/2013 | EP2569306A1 Heteroaryloxycarbocyclyl compounds as pde10 inhibitors |
| 03/20/2013 | EP2569299A1 Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors |
| 03/20/2013 | EP2569017A1 Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1 |
| 03/20/2013 | EP2568996A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases |
| 03/20/2013 | EP2568993A1 Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
| 03/20/2013 | EP2568988A1 Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt |
| 03/20/2013 | EP2568972A2 Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan |
| 03/20/2013 | EP2568971A1 Canagliflozin containing tablets |
| 03/20/2013 | CN1606554B Beta-lactamyl vasopressin v1a antagonists |
| 03/20/2013 | CN102985544A Organic compositions to treat beta-enac-related diseases |
| 03/20/2013 | CN102985405A Heterocyclic compound, and p27 kip1 degradation inhibitor |